+

SG11201805493YA - Binding members with altered diversity scaffold domains - Google Patents

Binding members with altered diversity scaffold domains

Info

Publication number
SG11201805493YA
SG11201805493YA SG11201805493YA SG11201805493YA SG11201805493YA SG 11201805493Y A SG11201805493Y A SG 11201805493YA SG 11201805493Y A SG11201805493Y A SG 11201805493YA SG 11201805493Y A SG11201805493Y A SG 11201805493YA SG 11201805493Y A SG11201805493Y A SG 11201805493YA
Authority
SG
Singapore
Prior art keywords
sawston
iontas
international
high street
binding members
Prior art date
Application number
SG11201805493YA
Inventor
Vellatt Aneesh Karatt
John Mccafferty
Sachin Surade
Tim Luetkens
Edward Masters
Michael Dyson
Original Assignee
Iontas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1600341.0A external-priority patent/GB201600341D0/en
Priority claimed from GBGB1621070.0A external-priority patent/GB201621070D0/en
Application filed by Iontas Ltd filed Critical Iontas Ltd
Publication of SG11201805493YA publication Critical patent/SG11201805493YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/14—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Structural Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 July 2017 (13.07.2017) WIPO I PCT (10) International Publication Number WO 2017/118761 Al 1111111111111101110111111111110101111101110111011111101111111111011111111111110111111 (51) International Patent Classification: C12N 15/10 (2006.01) (21) International Application Number: PCT/EP2017/050337 (22) International Filing Date: 9 January 2017 (09.01.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1600341.0 8 January 2016 (08.01.2016) GB 1621070.0 12 December 2016 (12.12.2016) GB (71) Applicant: IONTAS LTD [GB/GB]; 82B High Street, Sawston, Cambridge Cambridgeshire CB22 3HJ (GB). (72) Inventors: KARATT VELLATT, Aneesh; Iontas Ltd, 82B High Street, Sawston, Cambridge Cambridgeshire CB22 3HJ (GB). MCCAFFERTY, John; Iontas Ltd, 82B High Street, Sawston, Cambridge Cambridgeshire CB22 3HJ (GB). SURADE, Sachin; Iontas Ltd, 82B High Street, Sawston, Cambridge Cambridgeshire CB22 3HJ (GB). LUETKENS, Tim; 1163 E 200 S., Salt Lake City, UT 84102 (US). MASTERS, Edward,; Iontas Ltd, 82B High Street, Sawston, Cambridge Cambridgeshire CB22 3HJ (GB). DYSON, Michael; Iontas Ltd, 82B High Street, Sawston, Cambridge Cambridgeshire CB22 3HJ (GB). (74) Agents: SUTCLIFFE, Nicholas et al.; Mewburn Ellis LLP, City Tower, 40 Basinghall Street, London Greater London EC2V 5DE (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) W O 20 171187 / 6 1 Al (54) Title: BINDING MEMBERS WITH ALTERED DIVERSITY SCAFFOLD DOMAINS (57) : This invention relates to libraries of binding members that each comprise a fusion protein which contains a donor di - versity scaffold domain, such as a cysteine rich protein,inserted within a recipient diversity scaffold domain,such as an antibody con- stant or variable domain. Libraries and methods of generating libraries are provided, along with screening methods, binding mem- bers and methods of using the binding members.
SG11201805493YA 2016-01-08 2017-01-09 Binding members with altered diversity scaffold domains SG11201805493YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1600341.0A GB201600341D0 (en) 2016-01-08 2016-01-08 Diversity scaffolds
GBGB1621070.0A GB201621070D0 (en) 2016-12-12 2016-12-12 Diversity scaffolds
PCT/EP2017/050337 WO2017118761A1 (en) 2016-01-08 2017-01-09 Binding members with altered diversity scaffold domains

Publications (1)

Publication Number Publication Date
SG11201805493YA true SG11201805493YA (en) 2018-07-30

Family

ID=57868216

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805493YA SG11201805493YA (en) 2016-01-08 2017-01-09 Binding members with altered diversity scaffold domains

Country Status (11)

Country Link
US (1) US20190256840A1 (en)
EP (2) EP3277810B8 (en)
JP (2) JP7308505B2 (en)
KR (1) KR20180100132A (en)
CN (1) CN108473987B (en)
AU (1) AU2017205706B2 (en)
BR (1) BR112018013883A2 (en)
CA (1) CA3010231A1 (en)
GB (1) GB2562933B (en)
SG (1) SG11201805493YA (en)
WO (1) WO2017118761A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102423377B1 (en) 2013-08-05 2022-07-25 트위스트 바이오사이언스 코포레이션 De novo synthesized gene libraries
US10669304B2 (en) 2015-02-04 2020-06-02 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
CA2998169A1 (en) 2015-09-18 2017-03-23 Twist Bioscience Corporation Oligonucleic acid variant libraries and synthesis thereof
KR102794025B1 (en) 2015-09-22 2025-04-09 트위스트 바이오사이언스 코포레이션 Flexible substrates for nucleic acid synthesis
EP3384077A4 (en) 2015-12-01 2019-05-08 Twist Bioscience Corporation FUNCTIONALIZED SURFACES AND THEIR PREPARATION
SG11201901563UA (en) 2016-08-22 2019-03-28 Twist Bioscience Corp De novo synthesized nucleic acid libraries
US10417457B2 (en) 2016-09-21 2019-09-17 Twist Bioscience Corporation Nucleic acid based data storage
EA201991262A1 (en) 2016-12-16 2020-04-07 Твист Байосайенс Корпорейшн LIBRARIES OF OPTIONS OF IMMUNOLOGICAL SYNAPSIS AND THEIR SYNTHESIS
CN110892485B (en) 2017-02-22 2024-03-22 特韦斯特生物科学公司 Nucleic acid-based data storage
CA3056388A1 (en) 2017-03-15 2018-09-20 Twist Bioscience Corporation Variant libraries of the immunological synapse and synthesis thereof
MY206158A (en) 2017-05-24 2024-12-02 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
IL271205B2 (en) 2017-06-12 2025-02-01 Twist Bioscience Corp Methods for seamless nucleic acid assembly
US11407837B2 (en) 2017-09-11 2022-08-09 Twist Bioscience Corporation GPCR binding proteins and synthesis thereof
KR102637566B1 (en) 2017-10-20 2024-02-16 트위스트 바이오사이언스 코포레이션 Heated nanowells for polynucleotide synthesis
SG11202006460SA (en) 2018-01-04 2020-08-28 Twist Bioscience Corp Dna-based digital information storage
EP3814497A4 (en) 2018-05-18 2022-03-02 Twist Bioscience Corporation POLYNUCLEOTIDES, REAGENTS, AND METHODS FOR NUCLEIC ACID HYBRIDIZATION
CN109106942B (en) * 2018-09-18 2019-11-22 深圳瑞健生物科技有限公司 Application of a polypeptide capable of passing through the blood-brain barrier in the preparation of medicines
CN119708086A (en) 2018-12-26 2025-03-28 特韦斯特生物科学公司 Highly accurate de novo polynucleotide synthesis
US11492727B2 (en) 2019-02-26 2022-11-08 Twist Bioscience Corporation Variant nucleic acid libraries for GLP1 receptor
CN113785057A (en) 2019-02-26 2021-12-10 特韦斯特生物科学公司 Variant nucleic acid libraries for antibody optimization
WO2020257612A1 (en) 2019-06-21 2020-12-24 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
WO2021061829A1 (en) 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for crth2
WO2021061842A1 (en) 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for single domain antibodies
EP4384614A4 (en) * 2021-08-12 2025-07-02 Univ Hong Kong MATERIALS AND METHODS FOR THE COMPLETE DEFINITION OF ADAPTIVE IMMUNE RESPONSES
CN115035947B (en) * 2022-06-10 2023-03-10 水木未来(北京)科技有限公司 Protein structure modeling method and device, electronic device and storage medium

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
DE69230142T2 (en) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. METHOD FOR PRODUCING SPECIFIC BINDING PAIRS
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
ES2227512T3 (en) 1991-12-02 2005-04-01 Medical Research Council PRODUCTION OF ANTIBODIES AGAINST SELF-ANTIGENS FROM REPERTORIES OF ANTIBODY SEGMENTS FIXED IN A PHOTO.
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
ATE544785T1 (en) 2000-12-05 2012-02-15 Alexion Pharma Inc RATIONALLY DESIGNED ANTIBODIES
EP1660534A2 (en) * 2003-08-22 2006-05-31 MedImmune, Inc. Humanization of antibodies
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
EP1709972B1 (en) * 2005-04-05 2011-06-15 Affimed Therapeutics AG Use of an antibody against the laminin receptor or laminin receptor precursor for the diagnosis of cancer
EP2271758B1 (en) 2008-04-14 2018-09-12 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
WO2010017103A2 (en) * 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
US8921281B2 (en) * 2009-05-20 2014-12-30 Novimmune S.A. Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
AU2011326164B2 (en) * 2010-11-08 2016-05-05 The Board Of Trustees Of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
JP6684490B2 (en) * 2012-01-09 2020-04-22 ザ・スクリップス・リサーチ・インスティテュート Ultralong complementarity determining regions and uses thereof
EP2825653A4 (en) 2012-03-14 2016-01-20 Innovative Targeting Solutions Inc Generating targeted sequence diversity in fusion proteins
WO2014063012A1 (en) * 2012-10-19 2014-04-24 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
GB201302597D0 (en) 2013-02-14 2013-04-03 Univ Leeds Novel Synthetic Proteins
JP2016506974A (en) * 2013-02-15 2016-03-07 エスバテック − ア ノバルティスカンパニー エルエルシー Acceptor framework for CDR grafting
CN105814074B (en) * 2013-07-18 2020-04-21 图鲁斯生物科学有限责任公司 Humanized antibodies with ultralong complementarity determining regions
WO2015017146A2 (en) * 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
GB201407852D0 (en) * 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
GB201720351D0 (en) * 2017-12-06 2018-01-17 Iontas Ltd Selecting for developability in drug discovery

Also Published As

Publication number Publication date
JP7308505B2 (en) 2023-07-14
RU2018123301A (en) 2020-02-10
GB2562933A (en) 2018-11-28
BR112018013883A2 (en) 2018-12-18
GB201812040D0 (en) 2018-09-05
KR20180100132A (en) 2018-09-07
CN108473987B (en) 2024-01-02
CN108473987A (en) 2018-08-31
RU2018123301A3 (en) 2020-06-30
WO2017118761A1 (en) 2017-07-13
EP3277810A1 (en) 2018-02-07
CA3010231A1 (en) 2017-07-13
JP2022084834A (en) 2022-06-07
JP2019505206A (en) 2019-02-28
US20190256840A1 (en) 2019-08-22
EP3277810B8 (en) 2020-07-15
AU2017205706B2 (en) 2022-10-20
EP3277810B1 (en) 2020-05-27
GB2562933B (en) 2022-06-29
AU2017205706A1 (en) 2018-08-16
GB2562933A8 (en) 2018-12-19
EP3786292A1 (en) 2021-03-03
JP7539018B2 (en) 2024-08-23

Similar Documents

Publication Publication Date Title
SG11201805493YA (en) Binding members with altered diversity scaffold domains
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201910019PA (en) Microorganisms and methods for producing cannabinoids and cannabinoid derivatives
SG11201908820VA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201811184UA (en) Lag -3 binding members
SG11201909949XA (en) Targeted immunotolerance
SG11201805449PA (en) Methods of making chimeric antigen receptor -expressing cells
SG11201907857RA (en) Edible and biodegradable utensils
SG11201805532XA (en) Multivalent and multispecific 41bb-binding fusion proteins
SG11201907210YA (en) Policy communication via control plane signaling
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201900634VA (en) Chimeric antigen receptor
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201908280SA (en) "chimeric molecules and uses thereof"
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201808797XA (en) T cell receptors
SG11201908675PA (en) Computer-implemented system and method for performing transaction mixing on a blockchain
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201810887UA (en) Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
SG11201807474SA (en) Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies
SG11201805204WA (en) Nicotine particle capsule
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载